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Differences in systemic adaptive immunity
contribute to the ‘frequent exacerbator’
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Abstract
Background: Some COPD patients are more susceptible to exacerbations than others. Mechanisms underlying
these differences in susceptibility are not well understood. We hypothesized that altered cell mediated immune
responses may underlie a propensity to suffer from frequent exacerbations in COPD.
Methods: Peripheral blood mononuclear cells (PBMCs) were obtained from 24 stable COPD patients, eight frequent
exacerbators (≥3 diary-card exacerbations/year) and 16 infrequent exacerbators (< 3 diary-card exacerbations/year).
Detailed multi-parameter flow cytometry was used to study differences in innate and adaptive systemic immune
function between frequent and infrequently exacerbating COPD patients.
Results: The 24 COPD patients had a mean (SD) age of 76.3 (9.4) years and FEV1 1.43 (0.60)L, 53.3 (18.3)% predicted.
PBMCs of frequent exacerbators (FE) contained lower frequencies of CD4+ T central memory cells (CD4+ Tcm)
compared to infrequent exacerbators (IE) (FE = 18.7 %; IE = 23.9 %; p = 0.035). This observation was also apparent in
absolute numbers of CD4+ Tcm cells (FE = 0.17 × 10^6/mL; IE = 0.25 × 10^6/mL; p = 0.035). PBMCs of FE contained a
lower frequency of CD8+ T effector memory cells expressing HLA-DR (Human Leukocyte Antigen - D Related)
compared to IE COPD patients (FE = 22.7 %; IE = 31.5 %; p = 0.007).
Conclusion: Differences in the adaptive systemic immune system might associate with exacerbation susceptibility
in the ‘frequent exacerbator’ COPD phenotype. These differences include fewer CD4+ T central memory cells and
CD8+ T effector memory cells.
Trial registration: Not applicable.
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Background
Patients with chronic obstructive pulmonary disease
(COPD) are prone to periodic deteriorations in respiratory
health called exacerbations. Exacerbations impose a huge
burden on patients by reducing quality of life [1], acceler-
ating lung function decline [2] and increasing the risk of
death [3]. Exacerbations also pose a significant financial
burden on health care systems due to supplementary
treatment and increased hospital admissions [4, 5].
Most exacerbations are caused by infections with respira-
tory viruses and or alterations in the lung bacterial flora
termed dysbiosis. Mechanisms underlying an increased
susceptibility to infections are not well understood. Key
immune effector cells are abundant in the lungs of COPD
patients, and data have shown that they may fail to launch
an effective immune response when encountering an infec-
tious pathogen [6]. It is has been suggested that a deficient
immune response to pathogens may be attributed to
decreased effector cell function and an increased number
of suppressive T-regulatory cells [7]. In addition, Kalathil
[8] reported an increased number of exhausted effector T-
cells, characterised by expression of PD-1 (marker for
programmed cell death and cell exhaustion), in the sys-
temic circulation of patients with COPD compared to
healthy controls. Similarly, McKendry [9] found increased
PD-1 expression in CD8+ cells in lung tissue samples when
comparing COPD patients to healthy controls. These
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changes in the immune system in COPD may lead to an
immune paralytic state and thus predispose to recurrent
infections [7].
Although this hypothesis is attractive, translational
studies correlating changes in systemic immune function
with exacerbation frequency in COPD are lacking. In
particular, it is not known if such changes are seen in
the ‘frequent exacerbator’ exacerbation-susceptibility
phenotype [10]. The aim of the present study was to
investigate whether alterations in the cell mediated
immune system might underlie the frequent exacerbator
phenotype in COPD.
Methods
Study population
This analysis comprises data from a subset of stable
COPD patients from the London COPD cohort, col-
lected between May 2012 and April 2013. The setting,
recruitment and monitoring of the London COPD
cohort have been described previously [1, 2, 11–16]. In
short, patients with moderate to severe COPD were
included. Patients were trained to record daily any
worsening of respiratory symptoms on diary cards and
were subsequently followed for 1 year to record exacer-
bations of COPD.
COPD was defined as a post-bronchodilator Forced
Exhaled Volume in 1 s (FEV1) < 80 % predicted, a FEV1/
FVC ratio <70 %, and β2-agonist reversibility <12 %
and/or 200 ml. Patients with asthma were excluded. A
COPD exacerbation was defined as an increase of two
major symptoms (increased breathlessness, sputum vol-
ume or purulence) or one major and one minor symptom
(cold, increased cough, increased wheeze, sore throat).
Patients were categorised as frequent (FE) or infrequent
(IE) exacerbators defined as three or more versus two or
fewer diary card (symptom based) exacerbations per year,
respectively. We used three exacerbations for defining a
frequent exacerbator (FE) as we included both treated and
untreated exacerbations.
Blood samples
Blood samples from 24 stable COPD patients were
collected during the study period. Peripheral blood
mononuclear cells (PBMCs) were obtained from these
blood samples by means of density centrifugation and
stored at −180 °C in vapour-phase nitrogen in the UCL-
RFH Biobank prior to this analysis.
For thawing, PBMCs were re-suspended in a 30 mL
solution of pre-warmed (37 °C) RPMI-1640, Heat-
Inactivated Foetal Bovine Serum, Penicillin, Strepto-
mycin, and L-Glutamine (R20). The R20 containing the
PBMCs was then centrifuged for 5 min at 1500 rpm at
20 °C. Once centrifuged, the supernatant was removed
and the remaining pellets were re-suspended in 10 mL
of phosphate buffered saline (PBS). Next, viable cell
counts were determined by the trypan blue exclusion
(Neubauer hemocytometer). The cell concentration was
adjusted to 10 × 106/mL in supplemented PBS with
additional 1 % (volume/volume) foetal calf serum (FCS);
1 × 106 cells were dispensed into a 96 well plate for
antibody labelling.
Antibody labelling
We used a detailed immune screening panel developed at
The Royal Free Institute of Immunity and Transplant-
ation, specifically designed for studying infection suscepti-
bility and transplant rejection [17]. 1 × 106 PBMCs were
stained for a T-cell panel, an innate panel, and isotype
controls. Before antibody labelling, the suspensions were
incubated with purified human IgG (Sigma) to block Fc
receptors, reducing non-specific antibody binding.
The T-cell panel aliquots were incubated with com-
binations of CD3-PECy7 (clone SK7), CD4-v500 (clone
RPA-T4), CD8-v450 (clone RPA-T8), CD45R0-PECF594
(clone UCHL1), CD62L-APC (clone DREG-56), CD25-
APC Cy7 (clone M-A251), CD127-FITC (clone HIL-7R-
M21) (all from BD Biosciences), HLA-DR-PerCPCy5.5
(clone LN3) (eBioscience), and CD279-PE (clone EH
12.2H7) (Biolegend).
The innate panel aliquots were incubated with the
following combination of antibodies: CD3-PECy7 (clone
SK7), CD4-v500 (clone RPA-T4), CD8-v450 (clone RPA-
T8), CD45R0-PECF594 (clone UCHL1), CD56-APC
(clone NCAM16.2), CD16-APC H7 (clone 3G8), iNKT-
PE (clone 6B11), and Vd2-FITC (B6) (all from BD
biosciences).
For each sample in the T-cell panel an individual
isotype control was used. The isotype controls were
labelled with CD3-PECy7 (clone SK7), CD4-v500 (clone
RPA-T4), CD8-v450 (clone RPA-T8), CD45R0-PECF594
(clone UCHL1), IgG1k-APC Cy7 (clone MOPC-21)
(all from BD biosciences), IgG1k-APC (clone MOPC-
21), IgG1k-FITC (clone MOPC-21), IgG1k-PE (clone
MOPC-21) (Biolegend), and IgG2b-PerCPCy5.5 (clone
N/S) (eBioscience).
Flow cytometry
Flow cytometry analyses were performed with a four-
laser SORP (special order research product) BD LSRFor-
tessa™ cytometer using the BD FACSDiva™ software
V.6.0.1. The results were analysed using FlowJo X
10.0.7r2 software.
Statistical analysis
Cell populations in frequent exacerbators were compared
with infrequent exacerbators. Flow cytometry results were
expressed as a percentage of parent cell and total number
of cells calculated from the total lymphocyte count.
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Statistical analyses were performed using SPSS (IBM
SPSS Statistics, Version 22.0. Armonk, NY: IBM Corp).
Differences in percentages between groups were com-
pared using Fisher’s exact test and differences in total
number of cells using the Mann Whitney U test. A
two-tailed p value of < 0.05 was considered to indicate
significance. We did not correct for multiple testing
because we further analysed our data with principal
component analysis (PCA) and statistical multiplicity
does not affect PCA. The PCA is an unsupervised tech-
nique that is used to project high-dimensional data into
a new co-ordinate system. The projection of data into a
new co-ordinate system is performed to find meaning-
ful structure within extensive data sets; thereby deriving
parameters, so-called principal components, that best
describe the variance in an entire data set. The effect-
iveness of this analysis can be quantified by calculating
the relative amount of variation that each principle
component describes (expressed as a percentage of the
total variance).
We performed a stepwise multivariable linear regression
analysis with CD4+ memory T-cells as independent vari-
able and age (in years), smoking status (in pack-years),
severity of COPD (% FEV predicted) as dependent vari-
ables to identify which clinical parameters associate with
central memory T-cells.
Research ethics approval was obtained from the Re-
search Ethics Committee of the Royal Free Hampstead
NHS Trust where this work was undertaken (reference
number 05/Q0501/126). All subjects provided written
informed consent.
Results
Twenty-four patients participated in this study (eight
frequent and 16 infrequent exacerbators). The demo-
graphic and lung function data are presented in Table 1.
The mean (SD) age of the patients was 76.3 (9.4) years
and FEV1 53.3 (18.3) % predicted. There were no statisti-
cally significant differences between the frequent and
infrequent groups in age, gender, lung function parame-
ters, or smoking history.
Susceptibility to exacerbation
The flow cytometry results by exacerbation frequency
are presented in Tables 2 and 3 with the gating illus-
trated as Fig. 1. Susceptibility to exacerbation was associ-
ated with differences in acquired, but not innate
immune cells. Figure 2 depicts five representative plots
of the division of CD4+ T cells into memory subsets.
Frequent exacerbators had a lower frequency of CD4+
central memory T cells (CD4+ Tcm) compared to infre-
quent exacerbators (FE =18.7 %, IE =23.9 %, p = 0.035)
(Fig. 3). There was also a decrease in the absolute num-
ber of CD4+ Tcm cells between these groups (FE
=0.170 × 106/mL, IE =0.250 × 106/mL, p = 0.035). In
addition, we also found a lower percentage of activated
CD8+ T effector memory cells (CD8+ Tem HLA-DR) in
the frequent exacerbator group compared to the infre-
quent exacerbators (FE =22.7 %, IE =31.5 % p = 0.007,
Fig. 3). HLA-DR is a marker for early activation of T
cells. The absolute number of these cells (FE = 0.020 ×
106/mL, IE = 0.032 × 106/mL p = 0.759) was not sta-
tistically different. We found no statistically significant
differences in other subsets of adaptive immune cells,
including regulatory T cells (FE = 6.6 %, IE = 7.6 %,
p = 0.270). The expression of PD-1, a marker which
is expressed when cells are exhausted and/or will undergo
apoptosis, did not significantly differ in various adaptive
immune cells.
We did not define differences in innate immunity be-
tween FE and IE. For example, the proportion of natural
Killer (NK) cells (FE = 62.9 %, IE = 57.0 %, p = 0.473) and
the variety of NK cell subsets did not differ significantly
by susceptibility to exacerbation.
Table 1 Study population
Characteristics Frequent exacerbation (n = 8) Infrequent exacerbation (n = 16) p
Age (years) 80.6 ± 11.2 74.1 ± 8.0 0.169
Gender (male) 6 11 0.751
Exacerbation Frequency (/y) 3.82 ± 0.92 1.70 ± 0.81 NA
Smoking Status (ex-smoker) 7 10 0.204
Pack years 51.6 ± 30.4 44.9 ± 26.7 0.605
FEV1 (L) 1.21 ± 0.47 1.54 ± 0.64 0.163
FVC (L) 2.41 ± 0.58 2.96 ± 0.86 0.079
FEV1 %pred (%) 52.6 ± 19.4 53.7 ± 18.4 0.892
FVC %pred (%) 91.1 ± 32.7 82.9 ± 18.7 0.527
FEV1/FVC 0.52 ± 0.20 0.51 ± 0.15 0.928
Data expressed as mean ± SD except absolute number for gender and smoking status. Significance was calculated with chi-square or t test as appropriate. FEV1
forced expiratory volume in 1 s, FVC forced vital capacity, %pred the percentage of predicted
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Principal Component Analysis (PCA)
Data were further analysed using an unsupervised
PCA. This demonstrated that the first principal com-
ponent (PC) explained 20 % of the total variance.
Adding a second and a third covered 36 % and 48 %
respectively. Adding more PCs explained additional
variance, however, the contribution from further PCs
was limited (Fig. 4a). The principle component ana-
lysis parameter loadings (weighting coefficients) for
the first PC are plotted in Fig. 4b-d. The first PC as-
sociated most closely with cells expressing PD-1, and
there had been a trend to a statistically lower propor-
tion of CD4+ Tem cells expressing PD-1 in frequent
versus infrequent exacerbators (Table 2). The second
PC associated most closely with CD4+ Tcm. However,
the PCA was unable to differentiate frequent from
infrequent exacerbators and variance in the dataset
reflects high heterogeneity between COPD patients in
immunological profiles. This, in itself, is an important
observation.
Multiple linear regression analysis
To investigate which clinical characteristics were cor-
related with CD4+ central memory cells, we conducted
a multiple linear regression analysis (Table 4). This
analysis shows that the only factor significantly asso-
ciated with CD4+ central memory T-cells was exacerba-
tion frequency.
Table 2 Flow cytometry frequency results from COPD patients susceptible to frequent vs. infrequent exacerbations
Cell type FE (n = 8) Mean ± SD % / Median (IQR) % IE (n = 16) Mean freq. ± SD % / Median (IQR) % p
CD3+ 66.7 ± 12.0 77.2 ± 10.7 0.291
CD4+ 71.2 ± 17.0 73.6 ± 14.7 0.748
CD4+ HLA-DR+ 5.2 (2.3–7.0) 2.8 (2.3–4.9) 0.417
CD4+ PD-1+ 29.8 ± 9.2 27.8 ± 11.5 0.652
CD4+ Naive 37.5 ± 13.7 34.8 ± 13.3 0.651
CD4+ Tcm 18.7 ± 4.3 23.9 ± 6.9 0.035
CD4+ Tem 25.5 ± 11.1 25.6 ± 11.3 0.983
CD4+ Tem PD-1+ 60.2 ± 7.6 51.6 ± 13.5 0.059
CD4+ End 18.3 ± 4.9 15.8 ± 6.4 0.287
CD8+ 21.0 (12.6–31.3) 19.2 (12.5–25.8) 0.787
CD8+ HLA-DR+ 12.4 (4.2–23.4) 8.7 (6.4–20.9) 0.928
CD8+ PD-1+ 37.9 ± 11.1 36.6 ± 13.4 0.800
CD8+ Naïve 11.1 ± 6.5 14.3 ± 7.8 0.294
CD8+ Tcm 15.0 (6.7–17.5) 13.0 (10.9–18.8) 0.834
CD8+ Tem 43.9 ± 15.5 37.4 ± 8.6 0.300
CD8+ Tem HLA-DR+ 22.7 ± 13.5 31.5 ± 13.0 0.007
CD8+ End 27.4 ± 13.5 31.5 ± 13.0 0.488
Treg 6.6 ± 2.0 7.6 ± 2.0 0.270
Treg PD-1+ 39.2 ± 14.0 35.3 ± 12.7 0.521
NK 62.9 ± 18.8 57.0 ± 17.6 0.473
NK CD56bright 2.8 ± 2.1 3.5 ± 2.2 0.594
NK CD56dim 58.8 ± 19.8 53.4 ± 18.4 0.530
NK CD56brightCD16dim 1.8 (1.1–4.8) 2.5 (1.4–4.4) 0.697
NK CD56dimCD16bright 48.1 ± 20.3 45.9 ± 18.7 0.803
NK CD56 + CD56bright 3.5 (1.6–8.9) 6.5 (2.3–9.1) 0.358
NK CD56 + CD56dim 92.7 (87.9–98.3) 93.4 (90.6–97.6) 0.903
iNKT 1.6 (1.0–3.3) 1.2 (0.73–2.5) 0.417
γδ T 0.78 (0.34–1.4) 0.32 (0.17–0.70) 0.153
γδ T CD56+ 30.9 ± 15.4 32.3 ± 14.7 0.834
CD4+ : CD8+ ratio 45 ± 8.0 45 ± 6.2 0.959
Table shows the mean frequency (%) of cells based on their parent cell line. Significance was calculated using t test or Mann-Whitney U test as appropriate. PD-1+
cell marker for programmed cell death, End end-stage T cell, Treg regulatory T cell, NK natural killer, iNKT invariant natural killer T cell
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Discussion
We have shown that alterations in the cell mediated
immune system might explain why some patients with
COPD exacerbate more frequently than others. COPD
patients with frequent exacerbations showed lower num-
bers of CD4+ central memory T-cells and CD8+ activated
effector memory T-cells in peripheral blood when com-
pared with patients that have infrequent exacerbations.
This therefore provides a biological basis (or ‘endotype’)
for the exacerbation susceptibility phenotype in COPD
and suggests the presence of specific immune ‘signatures’
that may associate with exacerbation susceptibility.
We found a lower frequency and absolute number of
central memory CD4+ T-cells in COPD patients who
exacerbate frequently. Central memory cells are very
sensitive to cross-linking of their T-cell receptors and
rapidly express CD40 ligand in response [18]. Therefore,
they are very easily and quickly activated in response to
stimulation such that the immune system can respond
more rapidly and effectively to previously encountered
pathogens. Several studies have shown that CD4+ T
memory cells contribute to an effective defence against
specific viral pathogens (e.g. RSV and influenza) [19, 20].
Central memory CD4+ T-cells are stable and can main-
tain their population for many years [21]. This enables
CD4+ Tcm to provide long-term protection against
previously encountered pathogens. The lower frequency
of CD4+ Tcm cells we observed in this study may
predispose patients to viral respiratory infections and
therefore to frequent exacerbations.
Table 3 Flow cytometry absolute number of cells results from COPD patients susceptible to frequent vs. infrequent exacerbations
Cell type FE (n = 8) Mean abs No. ± SD/Median
abs No. (IQR) *10^6/ml
IE (n = 16) Mean abs No. ± SD/Median
abs No. (IQR) *10^6/ml
p
CD3+ 1.33 ± 0.38 1.42 ± 0.53 0.665
CD4+ 0.91 ± 0.19 1.07 ± 0.42 0.223
CD4+ HLA-DR+ 0.05 (0.02–0.07) 0.03 (0.02–0.04) 0.490
CD4+ PD-1+ 0.27 ± 0.09 0.28 ± 0.14 0.785
CD4+ Naive 0.34 ± 0.12 0.38 ± 0.21 0.505
CD4+ Tcm 0.17 ± 0.05 0.25 ± 0.12 0.035
CD4+ Tem 0.23 ± 0.12 0.26 ± 0.14 0.669
CD4+ Tem PD-1+ 0.14 ± 0.07 0.13 ± 0.07 0.666
CD4+ End 0.17 ± 0.06 0.17 ± 0.11 0.826
CD8+ 0.28 (0.13–53) 0.30 (0.13–0.40) 0.697
CD8+ HLA-DR+ 0.05 (0.01–0.09) 0.03 (0.01–0.06) 0.653
CD8+ PD-1+ 0.12 ± 0.09 0.11 ± 0.07 0.707
CD8+ Naïve 0.04 ± 0.02 0.04 ± 0.03 0.662
CD8+ Tcm 0.05 (0.02–0.06) 0.04 (0.02–0.07) 0.976
CD8+ Tem 0.16 ± 0.12 0.11 ± 0.07 0.368
CD8+ Tem HLA-DR+ 0.02 ± 0.01 0.03 ± 0.06 0.759
CD8+ End 0.13 ± 0.05 0.09 ± 0.06 0.575
Treg 0.06 ± 0.03 0.08 ± 0.04 0.173
Treg PD-1+ 0.02 ± 0.01 0.03 ± 0.01 0.296
NK 0.51 ± 0.24 0.30 ± 0.17 0.336
NK CD56bright 0.01 ± <0.01 0.01 ± <0.01 0.572
NK CD56dim 0.39 ± 0.12 0.18 ± 0.14 0.373
NK CD56brightCD16dim 0.01 (<0.01–0.02) 0.01 (<0.01–0.01) 0.490
NK CD56dimCD16bright 0.35 ± 0.14 0.15 ± 0.13 0.398
NK CD56 + CD56bright 0.02 (0.01–0.03) 0.01 (<0.01–0.02) 0.653
NK CD56 + CD56dim 0.29 (0.21–0.49) 0.26 (0.12 0.41) 0.490
iNKT 0.02 (0.01–0.03) 0.01 (0.01–0.03) 0.214
γδ T 0.01 (<0.01–0.02) <0.01 (<0.01–0.01) 0.153
γδ T CD56+ 0.01 ± 0.01 0.01 ± 0.01 0.544
Table shows the absolute number of cells in 1 ml of peripheral blood. Significance was calculated using t test or Mann-Whitney U test as appropriate. Abs No.
absolute number, PD-1+ cell marker for programmed cell death, End end-stage T cell, Treg regulatory T cell, NK natural killer, iNKT invariant natural killer T cell
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We hypothesise that the lower numbers CD4+ Tcm cells
might be caused by chronic antigen stimulation in the fre-
quent exacerbator phenotype, because long-term T-cell
memory (i.e. Tcm cells) fails to develop in conditions of
chronic antigenic stimulation. Numerous studies [22–28]
have found that infections with high loads of chronically
persisting antigen are characterised by sustained increased
frequencies of effector cells. However, these cells fail to
acquire essential features of memory cells, such as the IL-7
receptor; true for both CD4+ and CD8+ populations.
Chronic antigen stimulation in frequent exacerbators may
arise through multiple mechanisms, for example the past
history of repeated infections, or exposure to alterations in
the airway microbiome. It has long been recognised, for
Fig. 1 Gating strategy for adaptive immune cells. Lymphocytes were gated based on their characteristic scatter patterns. Lymphocytes were then
classified based on CD3 expression to identify T cells, which were divided into CD4+ and CD8+ T cells, prior to separation into their four main
subsets of naive, central memory (Tcm), effector memory (Tem), and end-stage T cells (Tend); this separation was based on the expression of
CD45R0 and CD62L. Tcm cells: CD45R0+/CD62L+, Tem cells: CD45R0+/CD62-, Naive T cells: CD45R0-/CD62L+, and Tend cells: CD45R0-/CD62L-. The
CD4+ and CD8+ T cells were subsequently analysed (including each of the main subsets) for expression of the markers CD127, HLA-DR, CD25 and
PD-1. Regulatory T-cells were identified based on the high expression of CD25 and low expression of CD127 in CD4+ T cells
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example, that the presence of potentially-pathogenic airway
bacteria on sputum culture associates with susceptibility to
exacerbation [16].
We also report a lower percentage of activated CD8+ ef-
fector cells in patients with frequent exacerbations. This
finding might also be linked to chronic antigen stimulation,
causing a downregulation of CD247 expression on CD8+
cells [29]. This process might be in part driven by myeloid
derived suppressor cells (MDSC). Downregulating CD247
expression by MDCSs leads to an immunosuppressive state
and defective effector cell function [29]. In support of this,
both a downregulation of CD247 expression in pulmonary
CD8 cells in COPD as well as higher levels of MDSCs have
been seen in patients with COPD [8].
That we did not report differences in exhausted effector
T-cells expressing PD-1 and regulatory T-cells might at
first appear contrary to this hypothesis. Previous work by
Kalathil did show differences in these type of immune
cells and inferred that this might render COPD patients
more susceptible to infections [8]. However, our findings
suggest that the effect of exhausted T-cells and regulatory
T-cells on exacerbation susceptibility may be limited. An
alternative hypothesis would be that the PD-1+ T-cells
and T-regulatory cells are indeed different in COPD pa-
tients compared to controls, but in the COPD population
not specifically different in the frequent exacerbator
phenotype compared to those less susceptible to exacerba-
tions. We hypothesise that continuous lung damage due
to smoking skews the systemic immune system in COPD
patients towards an exhausted paralytic state as seen in
studies by others [8, 9]. These changes in immune func-
tion lead to inadequate clearing of pathogens, and hence
persistent chronic antigen stimulation. This persistent
antigenic simulation, in return, directs the immune system
in a subgroup of ‘frequent exacerbator’ COPD patients to-
wards the changes seen in the present study.
Fig. 2 Representative plots of CD4+ T central memory cells in patients with frequent exacerbations and in patients who exacerbate infrequently.
CD4+ Tcm cells were identified as CD45R0+ and CD62L+ (top-right gate). The left plots present the memory profile belonging to a COPD patient
susceptible to frequent exacerbations and the right plots are from patients who exacerbate infrequently. Tem = CD4+ T effector memory
(bottom-right gate)
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Fig. 3 Susceptibility to Exacerbation in COPD is associated with reduced CD4+ Tcm and CD8+ Tem HLA-DR+. Graphs show the frequency (left)
and absolute number (right) of CD4+ Tcm cells in frequent exacerbators (FE) and infrequent exacerbators (IE). Horizontal lines indicate the mean.
Each dot represents an individual patient
Fig. 4 Principal component analysis. Graph presenting the results of the principal component analysis; this analysis was unable to concretely
stratify patients based on frequency of exacerbations, which suggests high heterogeneity. a Graph presenting the percentage of variance
explained, bars represent each separate principal component (PC), the line represents the cumulative percentage of these PCs. b-d The bar
graphs present the principle component analysis parameter loadings for the first three PCs. The bars illustrate the weighting coefficients, which
demonstrates the contribution each component (in this case: cell types) has in relation to their respective PC
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In addition, the current study defines no differences
within the systemic innate immunity (e.g. NK, iNKT,
and γδ T cells) between FE and IE COPD patients. The
explanation to the lack of differences might originate
from the primary function of the innate immunity,
which is predominantly to provide an initial defence
against pathogens. Considering we studied COPD pa-
tients in a stable state (i.e. no acute infection), the innate
immunity is not stimulated in the systemic circulation
and differences cannot be observed. It might prove to be
interesting investigating whether differences in the in-
nate immunity arise between FE and IE during an acute
COPD exacerbation.
Our findings are in agreement with the hypothesis that
lung inflammation in COPD may lead to impaired im-
munity to respiratory pathogens, facilitating COPD exac-
erbations [8]. Both local and systemic inflammatory
processes must balance between attenuating inflammation
caused by smoking and launching an effective immuno-
logical response against pathogens. Our data suggest that
in COPD patients susceptible to frequent exacerbations
this balance is, at least in part, tipped towards attenuating
the inflammatory response. It is tempting to speculate that
restoration of immune function could restore this balance
and might be of therapeutic benefit in COPD [7, 8].
Our higher dimensional statistical analysis did not show
any single principal component responsible for most of
the variance seen in our study. This highlights the hetero-
geneity associated with COPD. Whilst this might suggest
that our findings therefore simply reflect type 1 errors, we
think our findings truly reflects a systemic immune dys-
function because the direction of our results are in agree-
ment with other studies on immune dysfunction in COPD
[7, 8, 30]. However, the high heterogeneity in our sample,
important in itself, emphasises that besides systemic im-
mune dysfunction other mechanisms also likely play a role
in the susceptibility to exacerbations [31].
A limitation of our study is the relatively small sample
size and cross-sectional design, making it difficult to
make firm causal inferences. Another limitation is that
we did not perform functional analysis of the immune
cell subsets, such as cytokine response when stimulated
with pathogen exposure (e.g. RSV, influenza). Such a
functional analysis might have revealed differences
between FE and IE which would expand our understand-
ing of the immune response in the exacerbation phe-
notype. A strength of our study is the detailed flow
cytometry, the most comprehensive examination of vari-
ous subsets of the adaptive systemic immune function
ever reported in COPD. Moreover, it is one of the first
studies to establish systemic immunological differences
between phenotypes of COPD patients with regard to
exacerbation susceptibility. Future prospective studies in
a larger COPD population with frequent exacerbators
should be undertaken to confirm our results.
Conclusion
In conclusion, COPD patients who are subject to fre-
quent exacerbations have measurable differences in the
systemic adaptive immune system, which may make
them more susceptible to exacerbations. Therefore, the
exacerbation susceptibility phenotype in COPD has, at
least in part, a biological basis, which can be detected
with specific immune signatures in peripheral blood.
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